<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03655353</url>
  </required_header>
  <id_info>
    <org_study_id>ABY-025-MI301</org_study_id>
    <nct_id>NCT03655353</nct_id>
  </id_info>
  <brief_title>A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer</brief_title>
  <acronym>Affibody-3</acronym>
  <official_title>A Multicenter Phase II/III-study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Lindman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affibody</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Breast Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A large multi- center phase II/III study with 68Ga-ABY-025 PET and biopsies in patients with&#xD;
      advanced HER2-positive breast cancer, where the primary endpoint of the study is to find out&#xD;
      the correlation between the HER2 expression measured by 68Ga-ABY-025 PET and standard&#xD;
      histopathology from relevant tumor biopsies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Investigators will determine HER2 expression by ABY-PET without knowledge of the results from the biopsies (in Phase III part).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>HER2- expression by using 68Ga-ABY-025 PET.</measure>
    <time_frame>Approximately 10 days after study entry.</time_frame>
    <description>HER2-expression in tumors measured by 68Ga-ABY-025 PET, centrally analysed and result used for location of biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HER2-expression by analysing biopsy sample.</measure>
    <time_frame>Approximately 21 days after study entry.</time_frame>
    <description>HER2-expression in tumors by histopathology. Location of biopsy site based on HER2 expression seen in ABY-PET.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ABY-PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>68Ga-ABY-025 is used as tracer for PET scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ABY-PET</intervention_name>
    <description>Diagnostic PET for HER2 expression</description>
    <arm_group_label>ABY-PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent.&#xD;
&#xD;
          2. Age ≥18 years.&#xD;
&#xD;
          3. Histologically or cytologically confirmed HER2-positive or borderline positive (for&#xD;
             definition see below) adenocarcinoma of the breast.&#xD;
&#xD;
             HER2-positive defined as:&#xD;
&#xD;
               1. 3+ by immunohistochemistry [IHC] in &gt;10% of cell areas.&#xD;
&#xD;
               2. 2+ by IHC in &gt;10% of cell areas and HER2/CEP17 ratio ≥2.0 or HER2 copy number ≥&#xD;
                  6.0 by in situ hybridization [ISH]).&#xD;
&#xD;
                  HER2-borderline positive defines as:&#xD;
&#xD;
               3. 2+ by IHC and HER2/CEP17 ratio &lt;2.0 and/or HER2 copy number 4.0 - 6.0 by in situ&#xD;
                  hybridization [ISH]) (&quot;equivocal&quot;).&#xD;
&#xD;
               4. 2+ by IHC and HER2/CEP17 ratio &lt;2.0 and/or HER2 copy number &lt;4.0 by in situ&#xD;
                  hybridization [ISH]) (&quot;2+ ISH negative&quot;).&#xD;
&#xD;
               5. Known inhomogeneous HER2-expression in the primary tumor with HER2-positive areas&#xD;
                  &lt;10% (&quot;inhomogeneous&quot;).&#xD;
&#xD;
          4. Primary breast cancer planned for neoadjuvant therapy (Stage II-III, T2-4N0-3) or&#xD;
             metastatic (M1; at least 80 pts).&#xD;
&#xD;
          5. At least one tumor lesion ≥ 10 mm.&#xD;
&#xD;
          6. At least one tumor lesion available for biopsy.&#xD;
&#xD;
          7. Newly diagnosed or confirmed progression and planned for therapy with trastuzumab&#xD;
             emtansine or anti-HER2 targeted therapy(-ies) concomitant with chemotherapy&#xD;
             (HER2-positive cohort) or chemotherapy (HER2-negative patients).&#xD;
&#xD;
          8. WHO performance status ≤ 2.&#xD;
&#xD;
          9. Predicted survival &gt; 12 weeks.&#xD;
&#xD;
         10. Negative pregnancy test in women of childbearing potential (premenopausal or &lt;12&#xD;
             months of amenorrhea post-menopause and who have not undergone surgical&#xD;
             sterilization). Women of childbearing potential must use highly effective method of&#xD;
             contraception, i.e combined hormonal contraception, or progestogen-only hormonal&#xD;
             contraception, or intrauterine device, or intrauterine hormone-releasing system, or&#xD;
             bilateral tubal occlusion, or vasectomized partner, or sexual abstinence&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed HER2-negative breast cancer defined as IHC 0&#xD;
             or 1+.&#xD;
&#xD;
          2. Other manifest malignancy.&#xD;
&#xD;
          3. Serious uncontrolled concomitant disease including congestive heart failure that would&#xD;
             contraindicate the use of any anti-HER2 therapy.&#xD;
&#xD;
          4. Inadequate organ function, suggested by the following laboratory results:&#xD;
&#xD;
               -  Absolute neutrophil count &lt;1,500 cells/mm3&#xD;
&#xD;
               -  Total bilirubin ≥1.5 x ULN (unless the patient has documented Gilbert's syndrome)&#xD;
&#xD;
               -  AST (SGOT) or ALT (SGPT) &gt;5.0 × ULN&#xD;
&#xD;
               -  Serum creatinine clearance &lt;30 ml/min&#xD;
&#xD;
          5. Patients of childbearing potential and sexually active and not willing to use highly&#xD;
             effective contraceptive.&#xD;
&#xD;
          6. Assessed by the Investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Lindman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lena Franklin, BSc</last_name>
    <phone>+46 18 6111761</phone>
    <email>lena.franklin@akademiska.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tora Sundin</last_name>
    <phone>+46 18 6172428</phone>
    <email>tora.sundin@akademiska.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Section for Clinical Research &amp; Development Unit</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tora Sundin</last_name>
      <email>tora.sundin@akademiska.se</email>
    </contact>
    <contact_backup>
      <last_name>Lena Franklin</last_name>
      <email>lena.franklin@akademiska.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University Hospital</investigator_affiliation>
    <investigator_full_name>Henrik Lindman</investigator_full_name>
    <investigator_title>Coordinating Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

